Today marks an important milestone for SBI Canada’s Phase III RCT entitled “Fluorescence Imaging of Carcinoma During Breast Conserving Surgery”, as the first patient surgery was performed successfully at Orlando Health in Orlando, Florida. (ClinicalTrials.gov Identifier: NCT04815083)
This trial utilizes the tumor selectivity of 5-ALA combined with the handheld Eagle fluorescence imaging device to enable surgeons to conduct improved intraoperative margin assessment and fluorescence-guided breast conserving surgery.
Recruitment of additional clinical trial sites is underway and expected to include 20 surgical centers across Canada and the Unites States, including Princess Margaret Cancer Center.